
Germany’s Formycon (FSE: FYB) and India’s Zydus Lifesciences (BOM: 532321) jointly announced that the US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab).
To the best of the companies’ knowledge, this is the first publicly announced acceptance by the FDA of an application for a biosimilar of Keytruda, which is marketed by Merck & Co (NYSE: MRK). And generated sales of $31.7 billion in 2025.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze